Introduction
Thiol isomerases comprise the thioredoxin superfamily of oxidoreductases, characterised by the presence of one or more thioredoxin-like domains containing the CXXC motif [1] .
Over the last decade thiol isomerases located at the cell surface, most prominently protein disulphide isomerase (EC 5.3.4.1), have emerged as regulators of platelet function [2] [3] [4] [5] [6] , and of tissue factor activity [7] [8] [9] . Cell surface protein disulphide isomerase (csPDI) influences both fibrin generation and platelet thrombus formation in mouse models (8) , confirming that csPDI is relevant to in vivo haemostatic regulation.
A further cellular action of csPDI relevant to haemostasis and vascular regulation is to facilitate delivery across the plasma membrane of nitric oxide (NO) signalling [10, 11] . Our own previous studies have shown that csPDI is required for the delivery into platelets of a range of NO redox derivatives [12] and that during this process csPDI undergoes thiol modification [13] . NO supplementation by means of donor drugs is a potentially useful antithrombotic strategy in patients suffering from cardiovascular disease due to endothelial dysfunction [14] , and the anti-thrombotic action of S-nitrosothiols (RSNOs) has attracted particular interest because certain of these compounds show evidence of platelet-selective action [15] . For example, administration of low doses of S-nitrosoglutathione (GSNO) to human patients produced platelet inhibition without significant vasodilation [16] . This suggests preferential NO signalling into platelets, perhaps via differences in GSNO metabolism between platelets and cells of the blood vessel wall. Because of the role of csPDI in NO delivery, it is important to establish whether there are differences in the expression or activity of this enzyme between platelets and vascular cells.
PDI displays both oxidase and reductase, as well as thiol isomerase activity [1] , however since the mechanism of its S-denitrosation of GSNO involves electron donation by the active site thiols [17] , measurement of its reductase activity is most relevant in this context. A novel fluorescent assay sufficiently sensitive to measure csPDI reductase activity has recently been published [18] and we have therefore used this technique, adapted in 96 well plate format, to compare csPDI on platelets, endothelial cells and vascular smooth muscle cells. Our aim was to identify differences in csPDI expression between the cell types and to determine whether preferential NO delivery into platelets might be explained on this basis.
Materials and Methods

Chemicals
DAF-FM (4-amino-5-methylamino-2'7' difluorofluorescein) diacetate was obtained from Molecular Probes (Paisley, UK). GSNO (S-Nitroso-L-glutathione) was obtained from Alexis Biochemicals (Exeter, UK). Mouse anti-PDI antibody (1D3) conjugated R-Rhycoerythrin (PE) and PE-labeled isotype-matched control antibody (mouse IgG1) were obtained from Assay Designs (Exeter, UK). Live/Dead Fixable Dead Cell Stain Kits was obtained from Invitrogen (Paisley, UK). BCA protein assay kit was obtained from Thermo Scientific (Northumberland, UK). PD-10 Desalting columns were obtained from GE Healthcare (Buckinghamshire, UK). Dulbecco's Phosphate Buffered Saline (D-PBS and Fetal bovine serum (FBS) were obtained from Lonza Workingham Ltd (Slough, UK). All other chemicals were purchased from Sigma (Poole, UK).
Preparation of dieosin glutathione disulphide (di-E-GSSG)
The synthetic pseudosubstrate dieosin glutathione disulphide (Di-E-GSSG) was generated by incubation of GSSG (100 M) with a 10-fold molar excess of eosin isothiocyanate (1 mM) in phosphate buffer (100 mM potassium phosphate and 2mM EDTA, pH 8.8) overnight at room temperature as previously described [18] with minor modification. One hundred microliter aliquots were taken and passed down a PD-10 desalting column (Sephadex G-25) using 0.1 M potassium phosphate buffer, pH 7.0, containing 2 mM EDTA, and one millilitre aliquots were collected. The eluted fractions were tested for fluorescence increase before and after the addition of DTT (10 mM) by monitoring at 545 nm with excitation at 525 nm. All fractions showing at least 10-fold increase in fluorescence were pooled and stored at -20C.
Preparation of washed platelets
Washed platelets were prepared as previously described [12] . Briefly, whole blood (20 ml) was obtained with informed consent, according to the Declaration of Helsinki, from healthy volunteers and drawn into 25 ml container containing 3 ml of acid citrate dextrose. Plateletrich plasma (PRP) was separated from other cellular components of blood by centrifugation twice at 170 g for 10 min, keeping the upper layer each time. PRP was acidified with 0.5 M citric acid to pH 6.2-6.5, and prostaglandin E 1 (1.5 M) and apyrase (2 units/ml) were added to prevent aggregation during subsequent centrifugation at 1000 g for 12 min. The platelet pellet was then resuspended in 1 ml HEPES-buffered saline (HBS) containing 140 mM NaCl, 2.7 mM KCl, 5mM Glucose and 10 mM HEPES (pH 7.3) and loaded on to a Sepharose 2B column (1.45 x 5.0 cm). The platelet fraction was eluted with HBS and the platelet count was adjusted to 10 8 /ml before use.
Cell culture
Human coronary artery endothelial cells (HCAEC), human coronary artery smooth muscle cells (HCASMC), and their culture mediums were purchased from PromoCell (Heidelberg, Germany), and cultured according to manufacturer's instructions. Cells were passaged using a solution of 0.125% trypsin and 0.02% EDTA in Dulbecco's PBS (D-PBS). Experiments were performed after 3-5 passages, and the cell count adjusted to 10 5 / ml before use.
Assay of PDI reductase activity
Reductase activity of cell surface thiol isomerases was monitored in a 96-well microplate fluorescence assay. Authentic PDI (10-100 nM) was incubated with Di-E-GSSG (150 nM) in or ionomycin at concentrations of 1-100 M, and cell surface thiol isomerase activity was then monitored over 45 min, as described above. In separate experiments, platelets were subjected to the trypsinisation protocol described above for detachment of vascular cells, and the effect of this on csPDI expression was assessed to see whether expression might be affected by differences in cell preparation procedure.
Flow cytometry analysis
Measurement of the entry of NO × (reactive nitrogen species) into cells
DAF-FM diacetate, a membrane-permeant fluorescent probe, was used for detecting intracellular NO x as previously described [12] . Cells were suspended in HBS and then incubated with DAF-FM diacetate (5 M) at 37 0 C for 30 min. The DAF-FM-loaded platelets were then separated from free probe on a Sepharose 2B column. Excess DAF-FM was separated from HCAEC and HCASMC by centrifugation. S-Nitroso-L-glutathione (GSNO)
at concentrations of 10 -7 -10 -3 M was then added to the cells (10 5 /mL) in PDI assay buffer.
Fluorescence intensity at 515 nm with excitation at 480 nm was measured over 30 min using the microplate reader. To take account of higher fluorescence in the larger cells, data for each cell type were expressed as a percentage of the maximum value, obtained using 1 mM GSNO. In experiments to determine the role of PDI in NO delivery, cells were pre-incubated with 100 µM phenylarsine oxide (PAO), a thiol isomerase inhibitor, at 37 0 C for 30 min before addition of 1 mM GSNO.
Statistical analysis
All data are expressed as mean ± SEM. One-way ANOVA was used for difference between data groups and dose response curves were compared using two-way ANOVA followed with Bonferroni post-hoc correction for multiple comparisons. Differences were considered significant when p < 0.05.
Results
Reductase activity of authentic PDI and platelet cell surface thiol isomerases
The fluorescent PDI reductase assay employing Di-E-GSSG, first described by Raturi and
Mutus [18] was successfully adapted for use in 96 well microplate format, as shown by reproducible and dose dependent activity of authentic PDI (Fig 1A) and of cell surface thiol isomerase on platelets (Fig 1B) , which was inhibited in a dose dependent manner by the thiol isomerase inhibitor PAO (Fig 2) .
Comparison of csPDI expression and thiol isomerase activity on platelets, endothelial cells and vascular smooth muscle cells
csPDI was detected by flow cytometry on platelets, HCAEC and HCASMC (Fig 3A) . Both endothelial and smooth muscle cells showed more variable expression than platelets (Fig 3B) and when compared in terms of percentage positive cells, the level of the expression on platelets was significantly higher than on HCAEC and HCASMC (Fig 3C , P < 0.01). Platelet csPDI expression was unchanged by exposure to the trypsin reagent used to detach vascular cells from culture flasks (data not shown), indicating that our results were not due to differences in cell preparation prior to flow cytometric analysis. Consistent with this, csPDI reductase activity was significantly greater on platelets than on HCAEC and HCASMC (P < 0.01), when results were normalized for cell protein, with platelets showing approximately 6-fold and 15-fold higher activity than HCAEC and HCASMC, respectively (Fig 4) . To take into account the effect of differences in surface area between the cell types, we measured the number of cells required to provide an equal amount (1 g) of protein as 68000, 380 and 540
for platelets, HCAEC and HCASMC, respectively. Estimates of platelet surface area range from 14 m 2 [19] to 22 m 2 [20] . The diameter of trypsinised HCAEC and HCASMC ranges from 10 -25 m (personal communication, Promocell, Heidelberg), so taking a mean value of 17.5 m, and assuming a spherical shape, for these cells, their average surface area can be estimated as 962 m 2 . Taking this value, and a mean platelet value of 18 m 2 , it can be calculated that the excess of platelet surface area in our experiments was 3.3-fold compared with HCAEC and 2.4-fold compared with HCASMC. Thus it appears that discrepancy in cell surface area does not fully account for the higher csPDI activity seen in platelets.
In experiments to determine the effect of cell activation on csPDI activity, stimulation with PMA and ionomycin significantly increased the reductase activity on platelets and HCASMC (p < 0.01), but no changes were detected on HCAEC (Fig 5A, 5B ).
GSNO mediated NO × entry into platelets, HCAEC and HCASMC
Compared with both HCAEC and HCASMC, intracellular NO x delivery from GSNO was greater in platelets (P < 0.001) (Fig 6A) . Because of differences in absolute DAF-FM fluorescence values between the different cell types, NO x delivery was normalized to the percentage of maximal signal obtained following exposure to a GSNO concentration of 1mM. The results showed a greater proportional increase in platelets than in the other cell types, indicating that platelets are better able than HCAEC and HCASMC to receive NO x at low concentrations of GSNO. When csPDI was blocked using PAO, the percentage inhibition of DAF-FM fluorescence following GSNO exposure was higher for platelets than for endothelial cells or smooth muscle cells (P < 0.05) (Fig 6B) , indicating that platelets rely more heavily on csPDI for NO x delivery.
Discussion
We have established techniques to measure the expression and reductase activity of surface thiol isomerases on different cell types. PDI is a prominent member of this surface population, however the Di-E GSSG assay and the PAO inhibitor used in our experiments are non-specific, so the functional activity detected may derive from other isomerases in addition to PDI. Flow cytometric determination of csPDI showed the highest percentage positivity on platelets, whereas both vascular smooth muscle and endothelial cells displayed a wider spread of expression, with some cells showing high activity but the majority being negative.
Functionally active thiol isomerase was higher on platelets than on either of the two vascular cell types, and this heightened activity on platelets was not fully accounted for by increased availability of cell surface area. In addition, platelets showed an increase in thiol isomerasedependent NO delivery.
The presence of csPDI has been documented on a variety of cell types [21] however the processes governing localisation of PDI to the cell surface are not fully determined. In hepatocytes PDI secretion is mediated by microtubular activity and attachment to the plasma membrane appears to involve electrostatic interactions. Secreted PDI continues to display the KDEL endoplasmic reticulum (ER) retention signal and it is speculated that secretion may arise via leakage from a salvage pathway whose function is to recycle proteins to the ER [22] .
Several groups have shown that PDI is present inside endothelial cells and that it is upregulated under conditions of hypoxia [22] [23] [24] [25] , during which it becomes a target for Snitrosylation [26] . It is not yet clear whether PDI becomes upregulated on the cell surface in hypoxia. Endothelial cells in culture also express PDI on their exofacial surface in a punctuate distribution, possibly reflecting a concentration at cellular projections [9, 27] . This csPDI regulates the adhesive properties of both thrombospondin [27] and of its binding partner integrin α v β 3 [28] , and in addition catalyses transnitrosation of endothelial target molecules [29] . In contrast, experiments performed using mouse models of thrombus formation indicate that, in vivo, csPDI is not expressed on the endothelial surface of the unperturbed vessel wall, but that it accumulates rapidly following vascular injury [30, 31] .
The observed kinetics of csPDI accumulation under such circumstances suggest that it derives from both disrupted vascular cells and also from platelets adhering at the site of injury. csPDI has been detected on endothelial cells by flow cytometry [9] and in one study [28] the percentage of endothelial cells showing positivity for csPDI was much higher than our observed results. This discrepancy may arise from our use of primary cells in contrast to the EA.hy926 cell line (derived from fusion of endothelial and lung carcinoma cells) used in the earlier study.
PDI is present inside vascular smooth muscle cells and shows a shift to the membrane fraction (detectable by both western blotting and increased refolding activity) following cell stimulation with angiotensin II. Under these conditions membrane-associated PDI appears to co-localise with and regulate the activity of NADPH oxidase [32] . In similar fashion, activation of platelets is associated with increased secretion of both PDI [33] and a range of other thiol isomerases which go on to modulate various aspects of platelet function [34, 35] . It should be noted, however, that csPDI is also present on the surface of resting platelets [33, 36] , so activation is not required for csPDI to be displayed. We found that cell activation with PMA and ionomycin brought about an increase in thiol isomerase activity on both platelets and smooth muscle cells, however this effect was not apparent in endothelial cells.
PMA and ionomycin were deliberately chosen in order to stimulate generic intracellular signaling pathways (involving protein kinase C and intracellular calcium, respectively), so the variation in response between the cell types was not due to differential expression of particular agonist receptors. Interestingly, in hepatocytes the extracellular secretion of PDI was actually reduced by cellular stress in the form of tunicamycin treatment or heat shock [22] , so it is clear that the effects on surface thiol isomerases of cell stress / stimulation are not uniform across cell types.
Our measurements of cell surface reductase activity were made using a 96 well plate adaptation of the original method described by Raturi and Mutus [18] which allowed the use of small sample volumes. Our results clearly showed that platelets possess a more active surface, in this respect, than endothelial and smooth muscle cells. In parallel, the delivery of NO x into platelets was greater than into the other cell types, and the degree of thiol isomerase-dependence was greatest for platelets, as reflected in the loss of NO delivery brought about by the thiol isomerase inhibitor PAO. In these experiments, DAF-FM was used to detect the arrival of NO-related signalling inside cells. This fluorescent probe measures a range of NO / oxygen reaction products, therefore it is not possible to specify the identity of the NO derivative which is delivered. The NO donor used for these experiments was GSNO, so these results are relevant to the previously described clinical data indicating plateletselective action of this agent [16] .
Research into the mechanisms by which cells take up NO from impermeable donor compounds such as GSNO has highlighted two major pathways: NO release in the proximity of the plasma membrane by denitrosating enzymes (such as csPDI) (10) (11) (12) , and transnitrosation to cysteine followed by import of intact S-nitrosocysteine via the L-AT family of amino aid transporters [37] . We have previously argued that the former mechanism is more important in platelets [15] and the results of the present study are consistent with this hypothesis. We suggest that the platelet selective actions of GSNO result from platelet csPDI metabolising GSNO more rapidly than the endothelial lining of the blood vessel wall, this maximum value. Intracellular NO delivery was greater in platelets, compared with both HCAEC and HCASMC (P < 0.001), whereas there was no significant different between HCAEC and HCASMC. Data were analyzed by Two-way ANOVA followed by Bonferroni
